These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38515840)

  • 21. Lymphatic Uptake of a Highly Lipophilic Protease Inhibitor Prodrug from a Lipid-Based Formulation is Limited by Instability in the Intestine.
    Xie Y; Lu Z; Styles IK; Reddiar SB; Phillips ARJ; Windsor JA; Porter CJH; Han S; Trevaskis NL
    J Pharm Sci; 2024 Aug; 113(8):2342-2351. PubMed ID: 38582284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.
    Moj D; Maas H; Schaeftlein A; Hanke N; Gómez-Mantilla JD; Lehr T
    Clin Pharmacokinet; 2019 Dec; 58(12):1577-1593. PubMed ID: 31104266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate.
    Tsujii K; Hattori T; Imaoka A; Akiyoshi T; Ohtani H
    J Pharm Sci; 2018 May; 107(5):1430-1433. PubMed ID: 29291414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
    Asaumi R; Nunoya KI; Yamaura Y; Taskar KS; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):919-933. PubMed ID: 35570332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin.
    Gouin-Thibault I; Delavenne X; Blanchard A; Siguret V; Salem JE; Narjoz C; Gaussem P; Beaune P; Funck-Brentano C; Azizi M; Mismetti P; Loriot MA
    J Thromb Haemost; 2017 Feb; 15(2):273-283. PubMed ID: 27893182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
    Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate.
    Farhan N; Cristofoletti R; Basu S; Kim S; Lingineni K; Jiang S; Brown JD; Fang LL; Lesko LJ; Schmidt S
    CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):199-210. PubMed ID: 33449439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
    Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.
    Prueksaritanont T; Tatosian DA; Chu X; Railkar R; Evers R; Chavez-Eng C; Lutz R; Zeng W; Yabut J; Chan GH; Cai X; Latham AH; Hehman J; Stypinski D; Brejda J; Zhou C; Thornton B; Bateman KP; Fraser I; Stoch SA
    Clin Pharmacol Ther; 2017 Apr; 101(4):519-530. PubMed ID: 27943276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.
    Kollipara S; Ahmed T; Praveen S
    Xenobiotica; 2023 May; 53(5):366-381. PubMed ID: 37609899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
    Chen KF; Chan LN; Lin YS
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):493-512. PubMed ID: 32710209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
    Mulford DJ; Ramsden D; Zhang L; Michon I; Leifke E; Smith N; Jones HM; Scarpignato C
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):532-544. PubMed ID: 36896795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Consequence of Drug-Drug Interactions Influencing the Interplay between P-Glycoprotein and Cytochrome P450 3a: An Ex Vivo Study with Rat Precision-Cut Intestinal Slices.
    Li M; de Graaf IA; Siissalo S; de Jager MH; van Dam A; Groothuis GM
    Drug Metab Dispos; 2016 May; 44(5):683-91. PubMed ID: 26932816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.
    Akamine Y; Yasui-Furukori N; Uno T
    Curr Drug Metab; 2019; 20(2):124-129. PubMed ID: 30280663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.
    Umeyama Y; Fujioka Y; Okuda T
    Xenobiotica; 2014 Dec; 44(12):1135-44. PubMed ID: 24937160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
    Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
    Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach.
    Schaller S; Martins FS; Balazki P; Böhm S; Baumgart J; Hilger RA; Beelen DW; Hemmelmann C; Ring A
    Br J Clin Pharmacol; 2022 Feb; 88(4):1722-1734. PubMed ID: 34519068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.